Form 4: Director Magda Marquet Receives Equity Grant at Immix

Director Magda Marquet was granted 6,250 restricted stock units and 12,500 stock options by Immix Biopharma, Inc.

Summary

• Director Magda Marquet received a grant of 6,250 restricted stock units (RSUs) on May 22, 2026.
• The director also received a grant of 12,500 stock options with an exercise price of $8.78 per share.
• The RSUs vest on the earlier of the one-year anniversary of the grant or the 2027 annual meeting.
• The stock options vest in equal monthly installments over 12 months, subject to continued service.
• Following these transactions, the director directly owns 52,342 shares and maintains an indirect interest in 20,000 shares via ALMA Life Sciences, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention mechanism established via vesting schedules for both RSUs and stock options.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of options and vesting of RSUs.

Risks

• Continued service requirements for vesting create dependency on the director's ongoing tenure.
• Market price volatility could impact the value of the granted equity instruments.

Future Outlook

The equity grants are subject to vesting conditions tied to the director's continued service and the 2027 annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure alignment between board members and shareholders.

Comparison to Industry Standards

• The use of 12-month vesting schedules for director equity is consistent with standard retention practices for small-cap biotech firms.
• The grant of both RSUs and options is a common dual-incentive structure used to balance immediate ownership with performance-based upside.

Corporate Governance

Related Party Transactions

• The reporting person is the Co-Founder and Co-CEO of ALMA Life Sciences, LLC, which holds 20,000 shares of the issuer.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of options and vesting of RSUs.

Next Steps

• Vesting of 6,250 RSUs on the earlier of May 22, 2027, or the 2027 Annual Meeting.
• Monthly vesting of 12,500 stock options over the next 12 months.

Key Dates

Keywords

Immix Biopharma, IMMX, Form 4, Insider Trading, Equity Compensation, Director Compensation